Fetal Brain Grafts and Parkinson's Disease
I have reservations about the enthusiastic tone of the report by Lindvall et al. (1) and the accompanying Research News article (2 Feb., p. 529) on the effects of fetal brain tissue transplantation in a single human patient. Lindvall et al. imply that the changes seen were caused by survival of the transplanted cells and the resultant reinnervation ofthe host brain. The Research News article implies that the effects were qualitatively different from the effects that have so far been seen with adrenal medulla grafts. Compelling altemative possibilities were not discussed. First, the role of patient expectations may not be trivial. The patient could not possibly have been naive with respect to the expectations associated with the procedure. In addition to the obvious pitfalls of a study based on a single human subject, the interest and attention accorded this procedure may have contributed to the clinical changes.
The magnitude of the clinical changes seen is impressive, although not necessarily more impressive than the changes seen after adrenal medulla transplantation in some studies. For example, in the study of Goetz et al. (2) , in which 18 patients received adrenal medulla grafts by means of the Madrazo et al. (3) procedure, an average decrease in "off" time from 52% of the waking day before surgery to 22% 3 months after transplantation was seen. This is almost identical to the change seen by Lindvall et al. (1) .
Also, increased fluorodopa uptake seen on a positron emission tomography scan is not entirely equivalent to cell survival. Improvement in the patient for other reasons, including recovery of dopaminergic terminals around the graft site, might result in such a change. There is some evidence, in fact, that recovery of endogenous dopaminergic terminals can contribute to the effects of brain grafts under certain circumstances (4 Lindvall et al. (1) are to be congratulated for their demonstration that transplantation of fetal tissue may be therapeutic in patients with neurodegenerative and neurotraumatic disorders. Positron emission tomography (PET) with 6-[F18]fluoro-L-dopa (6FD) revealed a 130% increase in the operated putamen's influx constant. The interpretation of Lindvall et al. is that this represented reinnervation of the putamen by surviving functional graft. However, another explanation is also consistent with their observations, namely, that the surgical procedure induced sprouting of fibers from endogenous, residual, surviving dopaminergic neurons. That dopaminergic fibers from which sprouting could occur are present pre-operatively is evident from the PET scan presented in figure 3 of their report.
We have conducted a series of experiments grafting different tissues into the basal ganglia of primates with hemiparkinsonian symptoms induced by methyl(phenyl)tetrahydropyridine. We have witnessed the capability of PET with 6FD to detect surviving, viable fetal mesencephalic allografts (2). However, we have seen similar alterations of 6FD-derived radioactivity in the area of graft placement that histologically proved to be secondary to neurite sprouting from host dopaminergic neurons (3, 4) . The changes in the authors' stereotactic technique, which they hypothesize as contributing to a greater survival of the implanted fetal cells (dopaminergic or nondopaminergic) ( Our current strategy is based on the idea of improving dopamine neurotransmission in the dopamine-depleted striatum of patients severely affected with PD. It is important to demonstrate that, as in animals with neurotoxin-induced experimental parkinsonism, neural grafts can improve parameters of dopaminergic neurotransmission in the striatum in PD and that such changes can be correlated with therapeutically significant neurological improvements. The patient described in our report is interesting because he is the first case in which such a correlation has been seen.
Positron emission tomography (PET) is probably the only noninvasive technique available today with which to obtain direct information about dopamine synthesis and 7 DECEMBER 1990 handling in the striatum in PD patients. The lmitations of this technique are primarily related to sensitivity (we have estimated that the variance between measurements amounts to up to 30%) and spatial resolution (which is about 8.5 x 8.5 mm with the present equipment). With these limitations in mind, PET scanning, with the use of '8F-fluorodopa as a tracer, should allow not only the detection of marked improvements in dopamine formation and retention, but also the observation of where in the striatal complex this change has taken place. As Miletich et al. point out, an increased fluorodopa uptake detected by PET does not, by itself, provide information on the biological mechanism(s) behind it. However, the design of our study, in which we focused all implant material in one area (putamen) on one side, made it possible to establish that the increase in fluorodopa uptake was confined to the area surrounding the implantation sites and to see that there were no measurable increases in the nongrafted striatal regions. Our interpretation of this change rests mainly on the experimental data in 6-hydroxydopamine-lesioned rats, where functional recovery has been correlated with the degree of dopaminergic fiber outgrowth from the implanted dopaminergic neurons into the adjacent host striatum [see our original references (1-3) ]. The suggestion that trophic stimulation of sprouting from the residual surviving dopamine neurons could contribute to the observed improvements is an interesting one, and both the NIH team (2) and the Rochester group (3) have provided some intriguing new data in mice and monkeys treated with methyl(phenyl)tetrahydropyridine (MPTP) that support this idea. Bankiewicz et al. (2) have pointed out that the improvement was graft induced, that is, induced by the implanted fetal mesencephalic tissue, and that the damage associated with the grafting procedure (which in this case was a cavity technique) was not sufficient to induce the effect. This raises the possibility that in MPTP-lesioned monkeys, at least, the efficacy of fetal mesencephalic tissue to improve striatal dopaminergic transmission could be due to a combination of two different beneficial effects-host reinnervation by the grafted neurons and trophic stimulation of host fiber sprouting. It remains unclear, however, whether the severely damaged dopamine system in the Parkinson-diseased brain can undergo this type of sprouting response, and if so whether such a response might be aborted by the ongoing disease process. It should also be pointed out that in our study the graft was placed in the most severely affected area of the striatum, where little residual dopamine innervation may remain.
Dose difference between the two PET scans is unlikely to have played a role in the interpretation of the result. Radiochemical purity of 6-L-('8F) fluorodopa was 98.9% for the preoperative study and 97.1% for the postoperative study. Chemical purities were 99.6% and 98.8%, respectively. Specific activities were 14.22 Mbq/4M and 6.19 Mbq/ ,uM. The graphical approach used to calculate the influx constant normalizes for activity injected. The 3-methoxy metabolite of fluorodopa does indeed cross the blood-brain barrier; although the concentration of this metabolite was not assayed, there is no a priori reason to suppose that a major change in the peripheral metabolism of fluorodopa occurred as a result of stereotactic neurosurgery.
